Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators

US11919911B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Sung David C. Kim · Westwood, US
• Zaixing Li · Yangpu District, CN
• Chui Lu · Shanghai, CN
• Danuta Lubicka · Peabody, US
• James Neef · Stow, US
• Hye-Yeon Park · Arlington, US
• Tejaskumar Pankajbhai Pathak · Boston, US
• Amir Masoud Sadaghiani · Dover, US
• Xilin Zhou · Arlington, US

Key dates

• Filing date: Jun 11, 2021
• Grant date: Mar 5, 2024
• Expiry date: Jun 11, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.